New combo therapy aims to slow advanced breast cancer in patients who relapsed
Disease control
Not yet recruiting
This study tests whether a combination of two drugs (fulvestrant and ribociclib) works better than standard treatments for people with a certain type of advanced breast cancer (HR+, HER2-). The cancer has returned after the patient finished a prior course of CDK4/6 inhibitors. Ab…
Phase: PHASE2 • Sponsor: Yeon Hee Park • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC